Jane Street’s Annovis Bio ANVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-251,157
Closed -$689K 11490
2025
Q4
$869K Buy
+251,157
New +$755K ﹤0.01% 6417
2025
Q3
Sell
-23,798
Closed -$51.6K 10711
2025
Q2
$51.6K Buy
+23,798
New +$47K ﹤0.01% 9161
2025
Q1
Sell
-68,107
Closed -$343K 9357
2024
Q4
$343K Buy
68,107
+47,901
+237% +$347K ﹤0.01% 7517
2024
Q3
$163K Buy
20,206
+10,083
+100% +$94.5K ﹤0.01% 8776
2024
Q2
$58.3K Buy
+10,123
New +$82K ﹤0.01% 8883
2024
Q1
Sell
-11,969
Closed -$224K 9125
2023
Q4
$224K Buy
+11,969
New +$106K ﹤0.01% 8046
2023
Q2
Sell
-14,870
Closed -$229K 8624
2023
Q1
$229K Buy
+14,870
New +$240K ﹤0.01% 7633

Other funds holding ANVS

Jane Street's ANVS Position: Q1 2026 in Review

Jane Street sold out of Annovis Bio (ANVS) in Q1 2026, closing a stake of 251,157 shares — an estimated $689K sold.

Jane Street first reported a position in ANVS in Q1 2023 and held it in 7 quarters. The position peaked at $869K in Q4 2025. 56 funds tracked by Wall St. Rank hold ANVS as of Q1 2026.

  • Jane Street reported no remaining Annovis Bio position as of Q1 2026 after selling out during the quarter.
  • Jane Street sold 251,157 Annovis Bio shares in Q1 2026, an estimated $689K.
  • Jane Street first reported a position in Annovis Bio in Q1 2023 and held it in 7 quarters.
  • Jane Street's Annovis Bio position peaked at $869K in Q4 2025.
  • 56 funds tracked by Wall St. Rank held Annovis Bio as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.